Payment overview · 2025
General Payments
$1,874.13
70 reported records · 19 companies
Healthcare provider profile · identity verified
Parminder Bobby Singh, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MARION, OH · NPI 1598756546
Verified facts
What the public records show
CMS Open Payments records show Parminder Bobby Singh, M.D. received $1,874.13 in general payments during 2025 across 70 reported records.
Boston Scientific Corporation accounted for 15.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Eliquis, Fanapt, Farxiga, Jardiance, Linzess, Mounjaro, Nurtec Odt, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 128 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 179 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 131 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1199 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 116 claims for Xifaxan by this doctor in 2024.
Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Fanapt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $286.28 | 15.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $226.45 | 12.1% | 15 | 2025 |
| CorVista Health, Inc. | Unresolved — no canonical attribution shown | $215.78 | 11.5% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $194.77 | 10.4% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $161.07 | 8.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $139.96 | 7.5% | 10 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $96.87 | 5.2% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $75.76 | 4.0% | 5 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $75.22 | 4.0% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $68.49 | 3.6% | 3 | 2025 |
| Avanos Medical | Unresolved — no canonical attribution shown | $56.78 | 3.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $50.95 | 2.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $48.58 | 2.6% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $47.64 | 2.5% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $36.40 | 1.9% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $32.70 | 1.7% | 2 | 2025 |
| CARDIVA MEDICAL, INC. | Unresolved — no canonical attribution shown | $27.88 | 1.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.22 | 1.0% | 1 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $14.33 | 0.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,874.13 | 70 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CorVista System Normalized: corvista system |
Device | CorVista Health, Inc. | $215.78 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $165.86 | 3 | 2025 |
Source payment records
|
|||||
| BodyGuardian Normalized: bodyguardian |
Device | Boston Scientific Corporation | $147.05 | 1 | 2025 |
Source payment records
|
|||||
| CDS broad portfolio offering Normalized: cds broad portfolio offering |
Device | Boston Scientific Corporation | $139.23 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $107.61 | 8 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $96.87 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $91.87 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $91.56 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $75.76 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $75.22 | 4 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $72.22 | 6 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $68.49 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $62.67 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $59.76 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $54.59 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $52.18 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $48.58 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $48.58 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $47.64 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $36.40 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $33.36 | 2 | 2025 |
Source payment records
|
|||||
| CARDIVA VASCADE 6/7F VCS Normalized: cardiva vascade 6 7f vcs |
Device | CARDIVA MEDICAL, INC. | $27.88 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.84 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $23.89 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.22 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.67 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.00 | 1 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $14.33 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.24 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $11.39 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $9.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1199 | exact normalized | Medicare Part D |
| FANAPT fanapt |
2025 | Fanapt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 189 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 128 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 49 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 131 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 62 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 68 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 59 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 116 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
49 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
39 | 11 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
59 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
189 | 17 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
64 | 22 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
68 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
128 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
179 | 28 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
131 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
62 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
66 | 66 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1199 | 132 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
38 | 38 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
116 | suppressed by CMS |
| Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | FANAPT open payments reported associated product |
CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535 |
Fanapt · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2175 | 405 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1556 | 251 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1442 | 300 |
| Amlodipine Besylate | Amlodipine Besylate | 1236 | 250 |
| Eliquis | Apixaban | 1199 | 132 |
| Gabapentin | Gabapentin | 1175 | 218 |
| Potassium Chloride | Potassium Chloride | 1172 | 190 |
| Furosemide | Furosemide | 1057 | 217 |
| Metoprolol Tartrate | Metoprolol Tartrate | 979 | 204 |
| Lisinopril | Lisinopril | 863 | 200 |
| Metformin Hcl | Metformin Hcl | 823 | 165 |
| Sertraline Hcl | Sertraline Hcl | 819 | 140 |
| Tamsulosin Hcl | Tamsulosin Hcl | 789 | 143 |
| Trazodone Hcl | Trazodone Hcl | 767 | 152 |
| Losartan Potassium | Losartan Potassium | 649 | 143 |
| Metoprolol Succinate | Metoprolol Succinate | 633 | 130 |
| Clopidogrel | Clopidogrel Bisulfate | 624 | 120 |
| Duloxetine Hcl | Duloxetine Hcl | 569 | 96 |
| Donepezil Hcl | Donepezil Hcl | 565 | 98 |
| Omeprazole | Omeprazole | 530 | 124 |
| Famotidine | Famotidine | 518 | 102 |
| Buspirone Hcl | Buspirone Hcl | 510 | 86 |
| Myrbetriq | Mirabegron | 508 | 43 |
| Mirtazapine | Mirtazapine | 482 | 86 |
| Divalproex Sodium | Divalproex Sodium | 475 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 475 | 82 |
| Carvedilol | Carvedilol | 416 | 85 |
| Quetiapine Fumarate | Quetiapine Fumarate | 362 | 61 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 356 | 98 |
| Hydrochlorothiazide | Hydrochlorothiazide | 355 | 91 |
| Allopurinol | Allopurinol | 331 | 60 |
| Simvastatin | Simvastatin | 323 | 82 |
| Midodrine Hcl | Midodrine Hcl | 318 | 56 |
| Warfarin Sodium | Warfarin Sodium | 317 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 315 | 59 |
| Levetiracetam | Levetiracetam | 300 | 48 |
| Citalopram Hbr | Citalopram Hydrobromide | 299 | 64 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 290 | 71 |
| Risperidone | Risperidone | 284 | 33 |
| Azithromycin | Azithromycin | 273 | 190 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 272 | 53 |
| Memantine Hcl | Memantine Hcl | 271 | 45 |
| Pravastatin Sodium | Pravastatin Sodium | 265 | 47 |
| Montelukast Sodium | Montelukast Sodium | 264 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 263 | 119 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 258 | 74 |
| Xarelto | Rivaroxaban | 250 | 34 |
| Fluoxetine Hcl | Fluoxetine Hcl | 245 | 38 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 237 | 36 |
| Tramadol Hcl | Tramadol Hcl | 237 | 63 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 236 | 55 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 231 | 45 |
| Ropinirole Hcl | Ropinirole Hcl | 231 | 44 |
| Hydralazine Hcl | Hydralazine Hcl | 226 | 55 |
| Finasteride | Finasteride | 223 | 41 |
| Benztropine Mesylate | Benztropine Mesylate | 217 | 22 |
| Bumetanide | Bumetanide | 215 | 48 |
| Lactulose | Lactulose | 215 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 199 | 71 |
| Meloxicam | Meloxicam | 199 | 52 |
| Doxycycline Hyclate | Doxycycline Hyclate | 198 | 128 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 196 | 60 |
| Spironolactone | Spironolactone | 194 | 50 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 192 | 42 |
| Ondansetron Hcl | Ondansetron Hcl | 190 | 92 |
| Farxiga | Dapagliflozin Propanediol | 189 | 17 |
| Olanzapine | Olanzapine | 187 | 39 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 187 | 23 |
| Alendronate Sodium | Alendronate Sodium | 185 | 33 |
| Aripiprazole | Aripiprazole | 182 | 28 |
| Trulicity | Dulaglutide | 179 | 28 |
| Januvia | Sitagliptin Phosphate | 175 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 173 | 46 |
| Ibuprofen | Ibuprofen | 170 | 57 |
| Glipizide | Glipizide | 169 | 44 |
| Methylprednisolone | Methylprednisolone | 165 | 127 |
| Prednisone | Prednisone | 162 | 69 |
| Sucralfate | Sucralfate | 162 | 37 |
| Lamotrigine | Lamotrigine | 160 | 17 |
| Topiramate | Topiramate | 159 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 158 | 22 |
| Dicyclomine Hcl | Dicyclomine Hcl | 156 | 20 |
| Alprazolam | Alprazolam | 154 | 35 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 150 | 87 |
| Baclofen | Baclofen | 144 | 25 |
| Clonidine Hcl | Clonidine Hcl | 144 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 143 | 95 |
| Levofloxacin | Levofloxacin | 143 | 98 |
| Oxybutynin Chloride | Oxybutynin Chloride | 140 | 30 |
| Celecoxib | Celecoxib | 137 | 43 |
| Ozempic | Semaglutide | 131 | 38 |
| Glimepiride | Glimepiride | 129 | 34 |
| Jardiance | Empagliflozin | 128 | 22 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 126 | 23 |
| Primidone | Primidone | 124 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 122 | 79 |
| Amiodarone Hcl | Amiodarone Hcl | 119 | 23 |
| Lovastatin | Lovastatin | 119 | 27 |
| Clonazepam | Clonazepam | 116 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 116 | 39 |
| Humalog | Insulin Lispro | 116 | 28 |
| Xifaxan | Rifaximin | 116 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 115 | 22 |
| Lorazepam | Lorazepam | 114 | 31 |
| Cephalexin | Cephalexin | 111 | 68 |
| Propranolol Hcl | Propranolol Hcl | 110 | 19 |
| Glyburide | Glyburide | 108 | 31 |
| Latanoprost | Latanoprost | 108 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 106 | 21 |
| Bupropion Xl | Bupropion Hcl | 106 | 22 |
| Meclizine Hcl | Meclizine Hcl | 105 | 35 |
| Atenolol | Atenolol | 104 | 27 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 104 | 67 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 101 | 22 |
| Divalproex Sodium Er | Divalproex Sodium | 100 | suppressed |
| Nystatin | Nystatin | 97 | 52 |
| Ezetimibe | Ezetimibe | 96 | 21 |
| Diazepam | Diazepam | 93 | 32 |
| Calcitriol | Calcitriol | 91 | 16 |
| Novolog | Insulin Aspart | 90 | 24 |
| Venlafaxine Hcl | Venlafaxine Hcl | 90 | 11 |
| Oxcarbazepine | Oxcarbazepine | 86 | suppressed |
| Pregabalin | Pregabalin | 82 | 24 |
| Sevelamer Carbonate | Sevelamer Carbonate | 82 | 16 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 80 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 78 | 18 |
| Fenofibrate | Fenofibrate Nanocrystallized | 77 | 16 |
| Hydrocortisone | Hydrocortisone | 76 | 46 |
| Paroxetine Hcl | Paroxetine Hcl | 76 | 17 |
| Fenofibrate | Fenofibrate | 74 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 73 | 13 |
| Torsemide | Torsemide | 73 | 16 |
| Tradjenta | Linagliptin | 71 | suppressed |
| Ondansetron Odt | Ondansetron | 70 | 37 |
| Memantine Hcl Er | Memantine Hcl | 69 | 11 |
| Methenamine Hippurate | Methenamine Hippurate | 69 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 69 | 11 |
| Naproxen | Naproxen | 68 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 68 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 67 | 32 |
| Nyamyc | Nystatin | 67 | 28 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 66 | 66 |
| Cimetidine | Cimetidine | 66 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 66 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 66 | 21 |
| Symbicort | Budesonide/Formoterol Fumarate | 64 | 22 |
| Nifedipine Er | Nifedipine | 63 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 63 | 25 |
| Fluconazole | Fluconazole | 62 | 43 |
| Paliperidone Er | Paliperidone | 62 | suppressed |
| Rexulti | Brexpiprazole | 62 | suppressed |
| Vascepa | Icosapent Ethyl | 61 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 60 | 16 |
| Humalog Kwikpen U-100 | Insulin Lispro | 60 | 24 |
| Metformin Hcl Er | Metformin Hcl | 60 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 59 | 22 |
| Rivastigmine | Rivastigmine Tartrate | 59 | suppressed |
| Vraylar | Cariprazine Hcl | 59 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 55 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 51 | 25 |
| Pioglitazone Hcl | Pioglitazone Hcl | 50 | 14 |
| Carbamazepine | Carbamazepine | 49 | suppressed |
| Insulin Lispro | Insulin Lispro | 49 | 12 |
| Linzess | Linaclotide | 49 | 13 |
| Amoxicillin | Amoxicillin | 48 | 39 |
| Zolpidem Tartrate | Zolpidem Tartrate | 48 | 16 |
| Digoxin | Digoxin | 45 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 44 | suppressed |
| Nitroglycerin | Nitroglycerin | 43 | 30 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 43 | suppressed |
| Verapamil Er | Verapamil Hcl | 43 | suppressed |
| Calcium Acetate | Calcium Acetate | 42 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 42 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 41 | 27 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 40 | 15 |
| Levemir Flexpen | Insulin Detemir | 40 | 14 |
| Metoclopramide Hcl | Metoclopramide Hcl | 40 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 40 | suppressed |
| Ketoconazole | Ketoconazole | 39 | 20 |
| Novolog Flexpen | Insulin Aspart | 39 | 14 |
| Synthroid | Levothyroxine Sodium | 39 | 11 |
| Cilostazol | Cilostazol | 38 | suppressed |
| Glipizide Er | Glipizide | 38 | suppressed |
| Haloperidol | Haloperidol | 38 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 38 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 38 | 38 |
| Trintellix | Vortioxetine Hydrobromide | 38 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Entresto | Sacubitril/Valsartan | 37 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 37 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 37 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 37 | suppressed |
| Budesonide | Budesonide | 36 | 12 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 36 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 36 | suppressed |
| Ranolazine Er | Ranolazine | 36 | suppressed |
| Lansoprazole | Lansoprazole | 35 | suppressed |
| Amantadine | Amantadine Hcl | 34 | suppressed |
| Estradiol | Estradiol | 34 | suppressed |
| Metolazone | Metolazone | 34 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 34 | suppressed |
| Valsartan | Valsartan | 34 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 32 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 32 | suppressed |
| Methotrexate | Methotrexate Sodium | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 30 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 30 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 30 | 13 |
| Promethazine Hcl | Promethazine Hcl | 29 | suppressed |
| Sodium Bicarbonate | Sodium Bicarbonate | 29 | suppressed |
| Victoza 3-Pak | Liraglutide | 29 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 29 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 28 | suppressed |
| Dexamethasone | Dexamethasone | 28 | 17 |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Mirabegron Er | Mirabegron | 28 | suppressed |
| Timolol Maleate | Timolol Maleate | 28 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 28 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 27 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 27 | suppressed |
| Phenobarbital | Phenobarbital | 27 | suppressed |
| Brilinta | Ticagrelor | 26 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 26 | 14 |
| Gemtesa | Vibegron | 26 | suppressed |
| Klayesta | Nystatin | 26 | 17 |
| Lidocaine | Lidocaine | 26 | 11 |
| Loperamide | Loperamide Hcl | 26 | 14 |
| Methocarbamol | Methocarbamol | 26 | suppressed |
| Carbamazepine Er | Carbamazepine | 25 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 15 |
| Metronidazole | Metronidazole | 25 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Phenytek | Phenytoin Sodium Extended | 25 | suppressed |
| Sevelamer Hcl | Sevelamer Hcl | 25 | suppressed |
| Vancomycin Hcl | Vancomycin Hcl | 25 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 24 | 22 |
| Droplet Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | 12 |
| Gentamicin Sulfate | Gentamicin Sulfate | 24 | 19 |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 23 | suppressed |
| Leflunomide | Leflunomide | 23 | suppressed |
| Mupirocin | Mupirocin | 23 | 13 |
| Nexium | Esomeprazole Magnesium | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | 11 |
| Invega Sustenna | Paliperidone Palmitate | 22 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 22 | suppressed |
| Levemir | Insulin Detemir | 22 | suppressed |
| Albumin (Human) | Albumin Human | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 17 |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 21 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 21 | 13 |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 20 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Methimazole | Methimazole | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 19 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 19 | suppressed |
| Insulin Aspart | Insulin Aspart | 19 | suppressed |
| Irbesartan | Irbesartan | 19 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 19 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 19 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 18 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 17 | suppressed |
| Colchicine | Colchicine | 17 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 17 | suppressed |
| Ibu | Ibuprofen | 17 | suppressed |
| Moxifloxacin | Moxifloxacin Hcl | 17 | suppressed |
| Roflumilast | Roflumilast | 17 | suppressed |
| Ertapenem | Ertapenem Sodium | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 16 | suppressed |
| Daptomycin | Daptomycin | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Sulindac | Sulindac | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Trospium Chloride | Trospium Chloride | 15 | suppressed |
| Cefdinir | Cefdinir | 14 | 11 |
| Clobetasol Propionate | Clobetasol Propionate | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Enulose | Lactulose | 14 | suppressed |
| Jantoven | Warfarin Sodium | 14 | suppressed |
| Linezolid-D5w | Linezolid In Dextrose 5% | 14 | suppressed |
| Mesalamine Dr | Mesalamine | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 14 | suppressed |
| Rybelsus | Semaglutide | 14 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 13 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Everolimus | Everolimus | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 13 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 13 | suppressed |
| Methylphenidate Er (La) | Methylphenidate Hcl | 13 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Budesonide Ec | Budesonide | 12 | suppressed |
| Fanapt | Iloperidone | 12 | suppressed |
| Glucagon Emergency Kit | Glucagon | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 12 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 12 | suppressed |
| Restasis | Cyclosporine | 12 | suppressed |
| Risperdal Consta | Risperidone Microspheres | 12 | suppressed |
| Trulance | Plecanatide | 12 | suppressed |
| Alogliptin | Alogliptin Benzoate | 11 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Eszopiclone | Eszopiclone | 11 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 11 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 11 | suppressed |
| Itraconazole | Itraconazole | 11 | suppressed |
| Mesalamine | Mesalamine | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 11 | suppressed |
| Valproic Acid | Valproic Acid | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
| Veltassa | Patiromer Calcium Sorbitex | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,874.13 · 70 records | Boston Scientific Corporation | AIRSUPRA, AREXVY, BREZTRI, BodyGuardian, Briviact, CAPLYTA, CARDIVA VASCADE 6/7F VCS, CDS broad portfolio offering, CREON, Cologuard Collection Kit, CorVista System, ELIQUIS, FANAPT, FARXIGA, JARDIANCE, Korlym, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, VYEPTI, Wegovy, XIFAXAN, ZEPBOUND | 25 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error